(RTTNews) - Drugmaker Mylan N.V. (MYL) announced Thursday its partnership with Indian generics pharmaceutical company Lupin Limited to commercialize a biosimilar to Enbrel (etanercept). Under the ...
Thousand Oaks, CA - The US Food and Drug Administration has approved expanded labeling for the TNF inhibitor etanercept (Enbrel, Amgen/Wyeth) in the treatment of psoriatic arthritis (PsA). The label ...
SAN DIEGO, CA—Etanercept is associated with a higher rate of improvement in height z-score over the first 2 years of therapy in patients with juvenile idiopathic arthritis (JIA), according to study ...
HONG KONG – Lupin Ltd. and Mylan NV will be working together on commercializing a biosimilar Enbrel (etanercept) drug, or YLB-113, in a deal that brings Lupin an up-front payment of $15 million and ...
BEIJING--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first ...
HERTFORDSHIRE, England, PITTSBURGH and MUMBAI, India, March 27, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Medicines Agency's Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback